Proteinuria clinical trials
7 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
- A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
- Empagliflozin Treatment in Kidney Transplant Recipients
- Proteinuria in Pre and Post Transplant
- Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center
- Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Proteinuria” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.